Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Selvita Extends Collaboration with Chiesi Farmaceutici

Published: Monday, January 13, 2014
Last Updated: Monday, January 13, 2014
Bookmark and Share
Collaboration started with fee-for-service chemical synthesis in 2011.

Selvita has extended its chemistry research collaboration with Chiesi Farmaceutici from Italy.

“We are very proud to be working for such renowned and innovative company as Chiesi. Chiesi projects always involve novel, challenging chemistry and they let us demonstrate the full potential of Selvita’s chemistry team, our broad knowledge, experience and skills.” said Dr Miroslawa Zydron, Director of Contract Chemistry Department at Selvita.

The collaboration between Chiesi and Selvita started with fee-for-service chemical synthesis in 2011. After the successful completion of several projects, it evolved into FTE-based collaboration in 2012-2013.

The joint projects support Chiesi proprietary drug discovery and development pipeline, which is focused on respiratory, cardiovascular and special care disorders.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Selvita Launches New Company
Bioinformatics and personalized medicine focused Ardigen.
Friday, September 25, 2015
Selvita Establishes its First Operations in the U.S.
The largest drug discovery company in Central and Eastern Europe opens offices in Cambridge, MA and San Bruno, CA.
Saturday, September 19, 2015
Selvita Team Grows to Over 250 People
The company will publish its results for H1 2015 on August 13, 2015.
Tuesday, August 11, 2015
Selvita Establishes its UK Subsidiary in Cambridge
New office will be responsible for supporting the ongoing projects for the UK and Northern Ireland customers.
Thursday, May 07, 2015
Selvita Initiates IND-enabling Studies for its First-In-Class PIM/FLT3 Inhibitor
Company has signed agreement with Aptuit for the preparation of selected studies for the IND/CTA data package.
Saturday, April 04, 2015
Selvita Expands its Proteomics Services Offer
Expansion includes highly sophisticated mass spectrometers, additional ultra HPLC systems; and microscale thermophoresis measurement devices.
Wednesday, March 25, 2015
Selvita Group Received a GMP Certificate
Certificate was issued for 3 years.
Wednesday, February 19, 2014
Selvita Announces Changes to Management Board
Company announces appointment of Dr. Miroslawa Zydron and Dr. Krzysztof Brzozka.
Wednesday, November 06, 2013
Selvita and Orion Pharma Achieve a Research Milestone in Alzheimer’s Disease Program
Selvita is responsible for early research on the program.
Monday, July 02, 2012
Selvita Signs Contract with Evestra
Delivery of a range of drug metabolism, pharmacokinetic and physicochemical studies.
Tuesday, September 27, 2011
Selvita Signs a Computational Chemistry Services Agreement with IPD, USA
Agreement aims to identify novel chemical compounds that inhibit the activity of a novel protein target, proposed by IPD.
Wednesday, April 06, 2011
Selvita Signs a Drug Discovery Services Contract with Rottapharm Madaus
The project is aimed to deliver Rottapharm Madaus a set of designed and synthesized compounds having therapeutic potential in an indicated area.
Thursday, July 22, 2010
Scientific News
Researchers Develop Classification Model for Cancers Caused by KRAS
Most frequently mutated cancer gene help oncologists choose more effective cancer therapies.
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Chromosomal Chaos
Penn study forms basis for future precision medicine approaches for Sezary syndrome
Enzyme Malfunction May be Why Binge Drinking Can Lead to Alcoholism
A new study in mice shows that restoring the synthesis of a key brain chemical tied to inhibiting addictive behavior may help prevent alcohol cravings following binge drinking.
Key to Natural Detoxifier’s Reactivity Discovered
Results have implications for health, drug design and chemical synthesis.
New Treatment for Obesity Developed
Researchers at the University of Liverpool, working with a global healthcare company, have helped develop a new treatment for obesity.
New Protein Found in Immune Cells
Immunobiologists from the University of Freiburg discover Kidins220/ARMS in B cells and demonstrate its functions.
Will Brain Palpation Soon Be Possible?
Researchers have developed non-invasive brain imaging technique which provides the same information as physical palpation.
Shaking Up the Foundations of Epigenetics
Researchers at the Centre for Genomic Regulation (CRG) and the University of Barcelona (UB) published a study that challenges some of the current beliefs about epigenetics.
Groundbreaking Computer Program Diagnoses Cancer in Two Days
Researchers have combined genetics with computer science and created a new diagnostic technology can with 85 per cent certainty identify the source of the disease and thus target treatment and, ultimately, improve the prognosis for the patient.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos